2025 ICD-10-CM Diagnosis Code C81.7

Other Hodgkin lymphoma

C81.7 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
The 2025 edition of ICD-10-CM C81.7 became effective on October 1, 2024.
This is the American ICD-10-CM version of C81.7 – other international versions of ICD-10 C81.7 may differ.

Applicable To

The following code(s) above C81.7 contain annotation back-references

that may be applicable to C81.7:

Clinical Information

A monoclonal b-cell lymphoproliferation in the vast majority of cases. It is characterized by a bimodal age distribution (15-30 years of life and late life) and is often associated with ebv infection. In less than 5% of cases it is a monoclonal proliferation of t-lymphocytes. Morphologically, it is characterized by the presence of reed-sternberg cells and mononuclear hodgkin cells. The reed-sternberg and mononuclear hodgkin cells are cd30 positive in nearly all cases and cd15 positive in the majority of cases.
The most common type of hodgkin lymphoma, which is a cancer of the immune system. Classical hodgkin lymphoma is marked by the presence of a type of cell called the reed-sternberg cell.

Code History

2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
2017 (effective 10/1/2016): Revised code
- New description: Other Hodgkin lymphoma
- 2016 description: Other classical Hodgkin lymphoma
2018 (effective 10/1/2017): No change
2019 (effective 10/1/2018): No change
2020 (effective 10/1/2019): No change
2021 (effective 10/1/2020): No change
2022 (effective 10/1/2021): No change
2023 (effective 10/1/2022): No change
2024 (effective 10/1/2023): No change
2025 (effective 10/1/2024): No change

Diagnosis Index entries containing back-references to C81.7:

Lymphoma (of) (malignant) C85.90
- HodgkinC81.9-
  - specified NEC C81.7- (classical)